Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.39 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | ADH1B | P00325 | 1/20 | 0.34 |
| ▸ | ADH1C | P00326 | 1/20 | 0.34 |
| ▸ | ADH1A | P07327 | 1/20 | 0.34 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.34 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 2/20 | 0.30 |
| ▸ | CA1 | P00915 | 2/20 | 0.30 |
| ▸ | CA2 | P00918 | 2/20 | 0.30 |
| ▸ | MMP2 | P08253 | 2/20 | 0.30 |
| ▸ | CA9 | Q16790 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25440013 | 0.98 | TSHR (0.38) | TSHRFDPSADH1BADH1CADH1A | |
| SCHEMBL20564725 | 0.94 | TSHR (0.36) | TSHRFDPSCTSKALOX5 | |
| SCHEMBL26325025 | 0.81 | TSHR (0.37) | TSHRFDPS | |
| SCHEMBL26324878 | 0.79 | TSHR (0.36) | TSHRFDPS | |
| SCHEMBL26324857 | 0.74 | TSHR (0.33) | TSHR | |
| SCHEMBL25439978 | 0.73 | MEN1 (0.43) | TSHR | |
| SCHEMBL26328040 | 0.73 | ADH1A (0.38) | TSHRFDPSADH1CADH1AS1PR1 | |
| SCHEMBL6063948 | 0.72 | THRB (0.42) | TSHRCA12CA1CA2MMP2 | |
| SCHEMBL26327648 | 0.72 | ADH1A (0.37) | TSHRFDPSADH1CADH1AS1PR1 | |
| SCHEMBL20565352 | 0.71 | KDM4E (0.40) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | WILLIAM MARSH RICE UNIVERSITY (US) | 2023-09-26 | — | — | US | disclosed |
| WO-2018213572-A9 | PREPARATION OF SECONDARY AMINES WITH ELECTROPHILIC N-LINCHPIN REAGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-12-13 | — | — | WO | disclosed |
| WO-2018213572-A1 | PREPARATION OF SECONDARY AMINES WITH ELECTROPHILIC N-LINCHPIN REAGENTS | WILLIAM MARSH RICE UNIVERSITY (US) | 2018-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11767291-B2 | Preparation of secondary amines with electrophilic N-linchpin reagents | PNMT, NCL, NPM1 | TSHR 2716/4885FDPS 2828/4885ADH1B 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.